Author Verified
RCT
Published: Aug 2016
ACE Report #9245
Ace Report Cover Metabolic Disorders

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates


Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Contributing Authors: SR Cummings JY Reginster HG Bone E Czerwinski PD Miller MA Bolognese RB Wagman C Wang JP Brown J Malouf N Pannacciulli BS Nedergaard A Singer

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.